82664-20-8 Usage
Uses
Used in Pharmaceutical Industry:
FLURITHROMYCIN is used as an antibacterial drug for treating various bacterial infections. Its potent antibacterial activity makes it a valuable asset in the fight against resistant bacteria and contributes to the development of new treatment options for patients.
Used in Research and Development:
FLURITHROMYCIN serves as a valuable compound for researchers in the field of microbiology and pharmaceuticals. Its unique structure and properties allow for the exploration of new drug development strategies, as well as the study of antibiotic resistance mechanisms and the development of novel solutions to combat them.
Pharmaceutical Applications
A semisynthetic derivative of erythromycin A, supplied for oral administration. It is stable at acid pH due to the presence of the fluorine atom at C-8 of the erythronolide A ring.It is active against most streptococci (including Str. pneumoniae and Str. agalactiae; MIC50 0.03 mg/L), Mor. catarrhalis, N. gonorrhoeae (MIC50 0.04 mg/L), C. trachomatis (MIC 0.06– 0.125 mg/L), M. genitalium (MIC50 0.007 mg/L) and U. urealyticum (MIC50 0.03 mg/L). It has little or no activity against H. influenzae and M. hominis. Activity against anaerobes is similar to that of erythromycin A. It displays cross-resistance with erythromycin A.A single 500 mg oral dose achieved a mean peak plasma concentration of 1.2–2 mg/L after 1–2 h. The apparent elimination half-life was 8 h and the volume of distribution 5.5 L/ kg. With repeated doses (500 mg orally every 8 h for 10 doses), plasma concentrations were 0.72 mg/L immediately before and 0.67 mg/L at 4 h after the last dose. Absorption is not significantly affected by food. After administration of a single 375 mg tablet of flurithromycin ethylsuccinate, the mean serum levels at 0.5 h were 0.43 ± 0.35 mg/L. The mean peak serum concentration (1.41 ± 0.49 mg/L) was achieved at 1 h. At 8 and 12 h, the serum levels were 0.14 (± 0.05) and 0.04 (± 0.04) mg/L, respectively. The apparent elimination half-life is 3.94 (± 1.42) h. The apparent half-life in artificial gastric juice was about 40 min.It is generally well tolerated and has been used successfully for the treatment of lower respiratory tract infections. Availability is limited.
Check Digit Verification of cas no
The CAS Registry Mumber 82664-20-8 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 8,2,6,6 and 4 respectively; the second part has 2 digits, 2 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 82664-20:
(7*8)+(6*2)+(5*6)+(4*6)+(3*4)+(2*2)+(1*0)=138
138 % 10 = 8
So 82664-20-8 is a valid CAS Registry Number.
InChI:InChI=1/C37H66FNO13/c1-14-24-37(10,46)29(42)21(5)28(41)34(7,38)17-35(8,45)31(52-33-26(40)23(39(11)12)15-18(2)48-33)19(3)27(20(4)32(44)50-24)51-25-16-36(9,47-13)30(43)22(6)49-25/h18-27,29-31,33,40,42-43,45-46H,14-17H2,1-13H3/t18-,19+,20-,21+,22+,23+,24-,25+,26-,27+,29-,30+,31-,33+,34+,35-,36-,37-/m1/s1
82664-20-8Relevant academic research and scientific papers
Preparation of (8S)-8-fluoroerythromycins with N-F fluorinating agents
-
, (2008/06/13)
(8S)-8-fluoroerythromycins are prepared by reacting 8,9-anhydroerythromycin 6,9-hemiacetals or an N-oxide thereof with a carboxylic acid and an N-F fluorinating agent. The anhydro starting material may be prepared in situ from erythromycins or an N-oxide
Fluorinated erythromycin compounds and a process for preparation
-
, (2008/06/13)
Fluorinated derivatives of erythromycins A, B, C and D, having antibiotic activity, are prepared, starting from 8,9-anhydroerythromycin 6,9-hemiacetals or their N-oxides, through the reaction with a compound capable of generating electrophilic reactive fluorine, the resulting reaction product undergoing thereafter a reduction, possibly together with a methylation, to the corresponding (8S)-8-fluoroerythomycins.
